Biogen's lecanemab receives FDA Breakthrough Therapy Designation in the United States
Show original
Glonghui, January 28｜Biogen's Litifilimab has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of cutaneous lupus erythematosus, a disease that currently has no targeted therapies.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
UBS: South Korea Could Become a Highlight for Luxury Groups
格隆汇•2026/02/26 12:47
Bernstein rates Circle as "Outperform" with a target price of $190
BlockBeats•2026/02/26 12:36
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$68,220.28
+3.66%
Ethereum
ETH
$2,065.69
+6.52%
Tether USDt
USDT
$1
+0.01%
XRP
XRP
$1.44
+3.16%
BNB
BNB
$625.37
+2.65%
USDC
USDC
$0.9999
-0.00%
Solana
SOL
$87.5
+4.97%
TRON
TRX
$0.2865
+0.34%
Dogecoin
DOGE
$0.09899
+4.03%
Cardano
ADA
$0.2912
+5.55%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now